SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing a surge in interest, with community members attributing the recent price action to upcoming satellite launches and potential government contracts. Community members are actively discussing technical analysis points, institutional investment, and the potential for ASTS to disrupt the telecom industry. Some traders express caution, referencing the company's history of missed deadlines and the broader economic climate.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies is trending following news that Martin Shkreli has taken a position in the company and set a near-term price target of $100, sparking considerable discussion among investors. The community is actively discussing the potential of the company's technology and the implications of Shkreli's involvement, with some expressing skepticism and others anticipating a significant price increase. High trading volume and recent price action suggest heightened interest in QCLS within the next-generation computing sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending amid discussions of its earnings report, where annualized recurring revenue increased, and the CEO highlighted the company's AI automation strategy. The community is focused on the potential for a short squeeze and positive long-term outlook, with some discussing potential price targets for 2026. Recent partnerships and analyst ratings are also key talking points.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid community speculation regarding potential catalysts, including an FDA meeting and buyout rumors, driving high volumes and short covering. Community members are actively discussing the possibility of a streamlined Phase 3 trial for oral VK2735 and potential acquisition offers from major pharmaceutical companies seeking to bolster their GLP-1 portfolios.  The stock's movement is further fueled by discussions around the competitive landscape within the weight loss and metabolic disease sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as the community anticipates upcoming catalysts, including a Type B meeting with the FDA on December 15th regarding its lead drug candidate, sonelokimab (SLK).  Optimism stems from the drug's potential in treating inflammatory and autoimmune diseases, as well as speculation around a possible buyout from a major pharmaceutical company.  Despite recent clinical trial setbacks and shareholder lawsuits, investors are closely watching for positive news that could significantly impact the stock's valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential for a buyout or strategic partnership, fueled by promising data in lung, prostate, and pancreatic cancers. Community talking points center on the company being significantly undervalued with a large short interest, positioning it for a potential squeeze. The discussion is around CADL's pipeline and proximity to BLA filing, which could increase its attractiveness in the biotech sector.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as the community discusses a potential short squeeze amid high short interest, as well as the implications of a vote regarding share authorization. Community members are actively debating the stock's potential, citing the company's AI solutions for defense and national security, while some traders express skepticism.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as community members discuss a recent rise and speculate on potential catalysts like a buyback program or anticipation of news related to their drug, Tonmya. Some believe the stock is still undervalued, while others urge caution and realistic expectations, given the company's history and market dynamics. Discussions also involve comparing TNXP to other biotech opportunities and analyzing potential revenue scenarios for Tonmya.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending amid a mix of bullish analyst upgrades and some community concern regarding slower product revenue growth forecasts. Some traders are pointing to insider selling and margin shrinkage as reasons to be bearish, while others see recent partnerships with Palantir and Anthropic, and growing AI adoption, as positive catalysts. Overall, the discussion revolves around valuation and whether Snowflake can maintain its high growth trajectory.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending following its recent earnings report, with community discussions focused on whether the results justify the stock's muted reaction and long-term potential. Despite an earnings beat and raised guidance, some express concern over revenue and the company's positioning in the competitive AI landscape. Analysts are weighing in with updated ratings and price targets, adding to the debate around CRM's future performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The stake sale comes on the heels of the company increasing its stake in TNF Pharmaceuticals in September by an additional $3 million.&nbsp;</li><li>PharmaCyte said that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.&nbsp;</li><li>The company said that monetizing its stake in Femasys will help strengthen its financial position.</li></ul> PharmaCyte Biotech, Inc. (PMCB) said on Tuesday that it sold its stake in Femasys Inc. (FEMY), thereby increasing its cash and marketable securities to about $20 million.The company had cash and marketable securities of only about $13.3 million as of the end of July. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pharmacyte.com/press-releases/detail/319/pharmacyte-biotech-successfully-monetizes-femasys-stake">said</a> that monetizing its stake in Femasys will help strengthen its financial position.Shares of <a href="https://stocktwits.com/symbol/PMCB">PMCB </a>traded 25% higher at the time of writing.<h2 class="st-heading-2">PharmaCyte’s Financial Position</h2>CEO Josh Silverman stated that the successful monetization of the Femasys position demonstrates the effectiveness of the strategic and disciplined capital allocation approach. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation,” he said.Overall, PharmaCyte now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash. The company highlighted its low stock price below $1 and added that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.The stake sale comes on the heels of the company increasing its stake in Q/C Technologies, formerly known as TNF Pharmaceuticals, in September by an additional $3 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PMCB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the news shows the company has ways to generate cash without doing share offerings.<stembedurl>https://stocktwits.com/MadBat/message/637404061</stembedurl>Another expects the stock to cross the $1 threshold.<stembedurl>https://stocktwits.com/cbt2020/message/637412358</stembedurl>PMCB stock fell 48% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-slips-after-q4-revenue-guidance-disappoints/cL52NcEREgI">Nio Stock Slips After Q4 Revenue Guidance Disappoints</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.

Equity

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.


Q/C Technologies, Inc. (QCLS) stock surged 15% in the premarket session and became the top trending ticker among equities on Stocktwits on Friday morning. The stock is on its way toward the $6 mark, last seen in August this year.The stock has garnered significant retail attention in recent days following the firm's announcement of a shift in focus to high-performance computing tailored for the cryptocurrency space. Momentum around quantum computing, triggered by recent&nbsp;advancements in both quantum hardware and software, along with efforts to build more powerful quantum machines, also helped build interest around the stock.Formerly known as&nbsp;TNF Pharmaceuticals Inc., the company changed its name to Q/C Technologies to reflect its focus towards quantum-class computing, catering to crypto and blockchain applications.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/QCLS">Q/C Technologies' stock</a>&nbsp;jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;On September 24, the company stated that it secured exclusive worldwide rights to a laser-based processor developed by LightSolver. This light-speed laser processing unit (LPU) boosts computing by leveraging the speed and efficiency of photons over traditional semiconductor methods.LightSolver’s LPU is said to reduce power usage by up to 90% while outperforming current graphics processing units (GPUs) and quantum computing platforms in both speed and reliability. In addition to performance improvements, the system provides enhanced security for blockchain networks, a feature of growing importance for decentralized finance and cryptocurrency protocols.Q/C Technologies’ stock has lost over 96% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/howard-lutnick-pushes-back-on-nvidia-uae-ai-chip-deal-report-says/chCu4zUR3fi">Howard Lutnick Pushes Back On Nvidia’s Multi-Billion-Dollar UAE AI Chip Deal? Report Says Delay Leaves Jensen Huang Frustrated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A quantum computer being built by the start-up IQM Germany is located in a data center.

QCLS Stock Surges 15% In Pre-Market Today, Inches Closer To $6 Mark 

The stock has garnered significant retail attention in recent days following the firm's announcement of a shift in focus to high-performance computing tailored for the cryptocurrency space. 

Current Price	$7.12
Prev Close	$4.67
Open	$5.49
Dividend Yield	0.00%
50-Day Moving Average	$3.90
Beta	0.94
Avg. Volume	246,311.84
PE Ratio	-0.03

52-Week High	$164.00
52-Week Low	$2.50
Market Capitalization	$19.46M
EPS (Annual)	-$1,114.54
Price to Book	0.98
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

QCLS
Q/C Technologies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QCLS News

QCLSQ/C Technologies Inc.